Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices.
Open accessThe DOI matches its Crossref record; 156 of the 160 references it cites were found in a registry or an index.
Abstract
HEPATITIS B VIRUS (HBV) IS TRANSMITTED VIA BLOOD OR SEXUAL CONTACT. PERSONS WITH CHRONIC HBV INFECTION ARE AT INCREASED RISK FOR CIRRHOSIS AND LIVER CANCER AND REQUIRE MEDICAL CARE. THIS REPORT UPDATES AND SUMMARIZES PREVIOUSLY PUBLISHED RECOMMENDATIONS FROM THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) AND CDC REGARDING THE PREVENTION OF HBV INFECTION IN THE UNITED STATES. ACIP RECOMMENDS TESTING ALL PREGNANT WOMEN FOR HEPATITIS B SURFACE ANTIGEN (HBSAG), AND TESTING HBSAG-POSITIVE PREGNANT WOMEN FOR HEPATITIS B VIRUS DEOXYRIBONUCLEIC ACID (HBV DNA); ADMINISTRATION OF HEPB VACCINE AND HEPATITIS B IMMUNE GLOBULIN (HBIG) FOR INFANTS BORN TO HBV-INFECTED WOMEN WITHIN 12 HOURS OF BIRTH, FOLLOWED BY COMPLETION OF THE VACCINE SERIES AND POSTVACCINATION SEROLOGIC TESTING; UNIVERSAL HEPATITIS B VACCINATION WITHIN 24 HOURS OF BIRTH, FOLLOWED BY COMPLETION OF THE VACCINE SERIES; AND VACCINATION OF CHILDREN AND ADOLESCENTS AGED <19 YEARS WHO HAVE NOT BEEN VACCINATED PREVIOUSLY. ACIP RECOMMENDS VACCINATION OF ADULTS AT RISK FOR HBV INFECTION, INCLUDING UNIVERSAL VACCINATION OF ADULTS IN SETTINGS IN WHICH A HIGH PROPORTION HAVE RISK FACTORS FOR HBV INFECTION AND VACCINATION OF ADULTS REQUESTING PROTECTION FROM HBV WITHOUT ACKNOWLEDGMENT OF A SPECIFIC RISK FACTOR. THESE RECOMMENDATIONS ALSO PROVIDE CDC GUIDANCE FOR POSTEXPOSURE PROPHYLAXIS FOLLOWING OCCUPATIONAL AND OTHER EXPOSURES. THIS REPORT ALSO BRIEFLY SUMMARIZES PREVIOUSLY PUBLISHED AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASEST GUIDELINES FOR MATERNAL ANTIVIRAL THERAPY TO REDUCE PERINATAL HBV TRANSMISSION.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![FIGURE 3 Pre-exposure evaluation for health care personnel previously vaccinated with complete, ≥3-dose HepB vaccine series who have not had postvaccination serologic testing* * Should be performed 1–2 months after the last dose of vaccine using a quantitative method that allows detection of the protective concentration of anti-HBs (≥10 mIU/mL) (e.g., enzyme-linked immunosorbent assay [ELISA]).](https://figures.cochat.ai/paper-figures/33a10c0a9fbd4aaeaee38fc22efcfceb/prevention-of-hepatitis-b-virus-infection-in-the-united-states-recommendations-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, vaccination coverage among the majority of adult populations at high risk aged ≥30 years (e.g., persons with multiple sex partners, MSM, and injecting drug users) has remained low (1320,1321); these groups account for the highest rates of preventable acute infections (12,1319,1322).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both passive and active PEP (simultaneous administration of HBIG [i.e., 0.06 mL/kg body weight] and hepatitis B vaccine at separate anatomic sites) and active PEP (administration of hepatitis B vaccination alone) have been demonstrated to be highly effective in preventing transmission after exposure to HBV (12).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent clinical trials reported a protective antibody response achieved among approximately 90% of participants receiving Heplisav-B, compared with 70.5%–90.2% of participants receiving Engerix-B (12).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
(1994) · PsycEXTRA Dataset · doi:10.1037/e546992006-001 · Cited by 1,714
Trépo, C., Chan, H. L. Y., & Lok, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60220-8 · Cited by 1,623
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit684 · Cited by 1,613
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267 · cited 2×
“8%) of persons who inject drugs (PWID) in a variety of settings (75) and 22.”
BackgroundMast, E. E., Weinbaum, C. M., Fiore, A. E., Alter, M. J., Bell, B. P., Finelli, L., Rodewald, L. E., Douglas, J. M., Janssen, R. S., & Ward, J. W. (2006) · PubMed · Cited by 1,132
Self-citationHIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
Thio, C. L., Seaberg, E. C., Skolasky, R., Phair, J., Visscher, B., Muñoz, A., & Thomas, D. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11913-1 · Cited by 1,099
Epidemiology of viral hepatitis and HIV co-infection
Alter, M. J. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.004 · Cited by 1,012 · cited 3×
“%) of persons who inject drugs (PWID) in a variety of settings (75) and 22.6% of PWID have evidence of past infection (75).”
BackgroundInfluentialMcMahon, B. J., Alward, W. L. M., Hall, D. B., Heyward, W. L., Bender, T. R., Francis, D. P., & Maynard, J. E. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/151.4.599 · Cited by 832 · cited 1×
“Infants, children aged <5 years, and immunosuppressed adults with newly acquired HBV infection typically are asymptomatic, whereas symptomatic illness is noted in 30%–50% of older children, adolescents, and adults (7,8,44,50).”
BackgroundWeinbaum, C. M., Mast, E. E., & Ward, J. W. (2009) · Hepatology · doi:10.1002/hep.22882 · Cited by 815
Self-citationBeasley, R. P., CHIN-YUN LEE, G., Roan, C.-H., Hwang, L.-Y., Lan, C.-C., Huang, F.-Y., & Chen, C.-L. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90624-4 · Cited by 813 · cited 1×
“HepB vaccine or HBIG given alone are 75% and 71% effective in preventing perinatal HBV transmission, respectively; their combined efficacy is 94% (29,52,117).”
Background(2005) · PsycEXTRA Dataset · doi:10.1037/e548682006-001 · Cited by 753
A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
Goldstein, S. T., Zhou, F., Hadler, S. C., Bell, B. P., Mast, E. E., & Margolis, H. S. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyi206 · Cited by 743
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Shimabukuro, T. T., Nguyen, M., Martin, D., & DeStefano, F. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.035 · Cited by 608 · cited 1×
“1 3 US Department of Health and Human Services/Centers for Disease Control and Prevention quality (12,13).”
BackgroundPrevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness
(2001) · American Journal of Public Health · doi:10.2105/ajph.91.1.31 · Cited by 589
SURVIVAL OF HEPATITIS B VIRUS AFTER DRYING AND STORAGE FOR ONE WEEK
BOND, W. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92877-4 · Cited by 584 · cited 2×
“HBV is highly infectious, can be transmitted in the absence of visible blood (22), and remains infectious on environmental surfaces for at least 7 days (2,3).”
Background(2001) · PsycEXTRA Dataset · doi:10.1037/e548302006-001 · Cited by 564
Lok, A. S. F., McMahon, B. J., Brown, R. S., Wong, J. B., Ahmed, A. T., Farah, W., Almasri, J., Alahdab, F., Benkhadra, K., Mouchli, M. A., et al. (2016) · Hepatology · doi:10.1002/hep.28280 · Cited by 552
Special Article: National Surveillance of Dialysis‐Associated Diseases in the United States, 2002
Finelli, L., Miller, J. T., Tokars, J. I., Alter, M. J., & Arduino, M. J. (2005) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2005.18108.x · Cited by 530
Risks of chronicity following acute hepatitis B virus infection: a review.
Hyams, K. C. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.4.992 · Cited by 521 · cited 1×
“, hemodialysis patients and persons with human immunodeficiency virus [HIV] infection) (54,55) and persons with diabetes (54).”
BackgroundZibbell, J. E., Iqbal, K., Patel, R. C., Suryaprasad, A. G., Sanders, K. J., Moore-Moravian, L., Serrecchia, J., Blankenship, S., Ward, J. W., & Holtzman, D. J. (2015) · PubMed Central · Cited by 507
Self-citationGenotypes and Genetic Variability of Hepatitis B Virus
Kramvis, A. (2014) · Intervirology · doi:10.1159/000360947 · Cited by 462 · cited 1×
“Infection or immunization with one genotype generally confers immunity to all genotypes (7,44,46,47).”
BackgroundSurveillance of vaccination coverage among adult populations—United States, 2015.
Williams, W. W., Lu, P.-J., O’Halloran, A., Kim, D. K., Grohskopf, L. A., Pilishvili, T., Skoff, T. H., Nelson, N. P., Harpaz, R., Markowitz, L. E., et al. (2017) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6611a1 · Cited by 442
Self-citationThe influence of age on the development of the hepatitis B carrier state
(1993) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.1993.0102 · Cited by 424
Lee, C., Gong, Y., Brok, J., Boxall, E. H., & Gluud, C. (2006) · BMJ · doi:10.1136/bmj.38719.435833.7c · Cited by 402 · cited 1×
“HepB vaccine or HBIG given alone are 75% and 71% effective in preventing perinatal HBV transmission, respectively; their combined efficacy is 94% (29,52,117).”
BackgroundMagnius, L. O., & Norder, H. (1995) · Intervirology · doi:10.1159/000150411 · Cited by 400 · cited 1×
“Nine serologic subtypes initially were described based on the heterogeneity of HBsAg: adrq+, adrq–, ayr, ayw1, ayw2, ayw3, ayw4, adw2, and adw4 (44,45).”
MethodZhou, W., Pool, V., Iskander, J. K., English-Bullard, R., Ball, R., Wise, R. P., Haber, P., Pless, R., Mootrey, G. T., Ellenberg, S. S., et al. (2003) · PubMed · Cited by 400
Self-citationKowdley, K. V., Wang, C. C., Welch, S., Roberts, H., & Brosgart, C. L. (2012) · Hepatology · doi:10.1002/hep.24804 · Cited by 400 · cited 2×
“5% among foreign-born persons (19), and the majority of chronic HBV infections in the United States are among Asians/Pacific Islanders.”
BackgroundImmunization Practices Advisory Committee (1991) · PsycEXTRA Dataset · doi:10.1037/e546382006-001 · Cited by 398
Risk of anaphylaxis after vaccination in children and adults.
McNeil, M. M., Weintraub, E. S., Duffy, J., Sukumaran, L., Jacobsen, S. J., Klein, N. P., Hambidge, S. J., Lee, G. M., Jackson, L. A., Irving, S. A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.048 · Cited by 381 · cited 1×
“In addition, no evidence of a causal association between rheumatoid arthritis (130), Bell’s palsy (131), autoimmune thyroid disease (132), hemolytic anemia in children (133), anaphylaxis (134), optic neuritis (135), Guillain-Barré Syndrome (136), sudden-onset sensorineural hearing loss (137), or other chronic illnesse…”
Background(2011) · PubMed · Cited by 380
Weinbaum, C. M., Williams, I., Mast, E. E., Wang, S. A., Finelli, L., Wasley, A., Neitzel, S. M., & Ward, J. W. (2008) · PubMed · Cited by 364
Self-citationWalker, T. Y., Elam-Evans, L. D., Singleton, J. A., Yankey, D., Markowitz, L. E., Fredua, B., Williams, C. L., Meyer, S. A., & Stokley, S. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6633a2 · Cited by 362
What Level of Hepatitis B Antibody Is Protective?
Jack, A. D., Hall, A. J., Maine, N., Mendy, M., & Whittle, H. C. (1999) · The Journal of Infectious Diseases · doi:10.1086/314578 · Cited by 354 · cited 2×
“Immunocompetent children and adults who have vaccine-induced anti-HBs levels of ≥10 mIU/mL 1–2 months after having received a complete HepB vaccine series are considered seroprotected and deemed vaccine responders (107).”
BackgroundThe Prevalence of Hepatitis B Virus Infection in the United States in the Era of Vaccination
Wasley, A., Kruszon‐Moran, D., Kuhnert, W., Simard, E. P., Finelli, L., McQuillan, G., & Bell, B. (2010) · The Journal of Infectious Diseases · doi:10.1086/653622 · Cited by 351 · cited 1×
“On the basis of national health survey data, it is estimated that approximately 850,000 persons are living with HBV infection (prevalence) in the United States (17,18).”
BackgroundAdverse Effects of Vaccines: Evidence and Causality
Stratton, K. R., Ford, A. Q., Rusch, E., & Clayton, E. W. (2013) · Cited by 348
Brown, R. S., McMahon, B. J., Lok, A. S. F., Wong, J. B., Ahmed, A. T., Mouchli, M. A., Wang, Z., Prokop, L. J., Murad, M. H., & Mohammed, K. (2016) · Hepatology · doi:10.1002/hep.28302 · Cited by 324
Bruce, M. G., Bruden, D., Hurlburt, D., Zanis, C., Thompson, G., Rea, L., Toomey, M., Townshend-Bulson, L., Rudolph, K., Bulkow, L., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv748 · Cited by 322 · cited 1×
“Most persons (88%) who receive a challenge dose of HepB vaccine 30 years after HepB vaccination as children or adults develop an antibody response of ≥10 mIU/mL indicating persistent immunity to HBV infection (108).”
BackgroundRisk of anaphylaxis after vaccination of children and adolescents.
Bohlke, K., Davis, R. L., Marcy, S. M., Braun, M. M., DeStefano, F., Black, S. B., Mullooly, J. P., Thompson, R. S., & for the Vaccine Safety Datalink Team (2003) · PEDIATRICS · doi:10.1542/peds.112.4.815 · Cited by 320
Hepatitis B and the Need for a Booster Dose
Leuridan, E., & Van Damme, P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir270 · Cited by 308 · cited 1×
“1 13 US Department of Health and Human Services/Centers for Disease Control and Prevention dose are considered protected, regardless of subsequent declines in anti-HBs (10,109).”
BackgroundOCCUPATIONAL EXPOSURE TO HEPATITIS B VIRUS IN HOSPITAL PERSONNEL: INFECTION OR IMMUNIZATION?
DIENSTAG, J. L., & RYAN, D. M. (1982) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113277 · Cited by 307 · cited 1×
“Before HepB vaccination was widely implemented, HBV infection was recognized as a common occupational risk among HCP (85,86).”
BackgroundSchillie, S. F., Murphy, T. V., Sawyer, M. H., Ly, K. N., Hughes, E., Jiles, R. B., de Perio, M. A., Reilly, M. L., Byrd, K. K., & Ward, J. W. (2013) · PubMed · Cited by 293
Self-citationNonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008.
Thompson, N. D., Perz, J. F., Moorman, A. C., & Holmberg, S. D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-1-200901060-00007 · Cited by 283
Kellerman, S. E., Hanson, D. L., McNaghten, A. D., & Fleming, P. L. (2003) · The Journal of Infectious Diseases · doi:10.1086/377135 · Cited by 282
Immunogenicity of Hepatitis B vaccines
Averhoff, F., Mahoney, F., Coleman, P., Schatz, G., Hurwitz, E., & Margolis, H. (1998) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(98)00003-8 · Cited by 275
McMahon, B. J. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.5.1051 · Cited by 273
Viral Hepatitis, Type B: Studies on Natural History and Prevention Re-Examined
Krugman, S., Overby, L. R., Mushahwar, I. K., Ling, C.-M., Frösner, G. G., & Deinhardt, F. (1979) · New England Journal of Medicine · doi:10.1056/nejm197901183000301 · Cited by 266 · cited 1×
“The average incubation period is 60 days (range: 40–90 days) from exposure to onset of abnormal serum ALT levels and 90 days (range: 60–150 days) from exposure to onset of jaundice (8,42,43).”
BackgroundPan, C. Q., Duan, Z., Bhamidimarri, K. R., Zou, H., Liang, X., Li, J., & Tong, M. J. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.10.041 · Cited by 265 · cited 1×
“Published evidence indicates that maternal antiviral therapy during pregnancy further reduces perinatal HBV transmission; hence, AASLD suggests antiviral therapy when maternal HBV DNA is >200,000 IU/mL (5,38,39).”
BackgroundEffect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination
Shaw, F. E., Guess, H. A., Roets, J. M., Mohr, F. E., Coleman, P. J., Mandel, E. J., Roehm, R. R., Talley, W. S., & Hadler, S. C. (1989) · Vaccine · doi:10.1016/0264-410x(89)90157-6 · Cited by 263
Hadler, S. C., Judson, F. N., O'Malley, P. M., Altman, N. L., Penley, K., Buchbinder, S., Schable, C. A., Coleman, P. J., Ostrow, D. N., & Francis, D. R. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.3.454 · Cited by 260 · cited 1×
“, hemodialysis patients and persons with human immunodeficiency virus [HIV] infection) (54,55) and persons with diabetes (54).”
BackgroundGish, R. G., Given, B. D., Lai, C.-L., Locarnini, S. A., Lau, J. Y. N., Lewis, D. L., & Schluep, T. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.008 · Cited by 259
Serological pattern ?anti-HBc alone?: Report on a workshop
Grob, P., Jilg, W., Bornhak, H., Gerken, G., Gerlich, W., G�nther, S., Hess, G., H�dig, H., Kitchen, A., Margolis, H., et al. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200012)62:4<450::aid-jmv9>3.0.co;2-y · Cited by 255
The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety
McNeil, M. M., Gee, J., Weintraub, E. S., Belongia, E. A., Lee, G. M., Glanz, J. M., Nordin, J. D., Klein, N. P., Baxter, R., Naleway, A. L., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.073 · Cited by 247 · cited 1×
“VSD can be used to assess hypotheses that arise from reviews of medical literature, reports to VAERS, changes in immunization schedules, or the introduction of new vaccines (14).”
BackgroundWeinbaum, C. M., Lyerla, R., & Margolis, H. S. (2003) · PubMed · Cited by 234
(2003) · PsycEXTRA Dataset · doi:10.1037/e546002006-001 · Cited by 232 · cited 1×
“7%) than among the general population (83,84), reflecting an overrepresentation of persons entering correctional facilities with risks for HBV infection (e.”
BackgroundImmunopathogenesis of hepatitis B virus infection
Chang, J. J., & Lewin, S. R. (2007) · Immunology & Cell Biology · doi:10.1038/sj.icb.7100009 · Cited by 211
Roberts, H., Kruszon‐Moran, D., Ly, K. N., Hughes, E., Iqbal, K., Jiles, R. B., & Holmberg, S. D. (2016) · Hepatology · doi:10.1002/hep.28109 · Cited by 205 · cited 1×
“On the basis of national health survey data, it is estimated that approximately 850,000 persons are living with HBV infection (prevalence) in the United States (17,18).”
BackgroundSummary of safety and efficacy data on a yeast-derived hepatitis B vaccine
André, F. E. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90525-1 · Cited by 203 · cited 1×
“The 3-dose HepB vaccine series produces a protective antibody response (anti-HBs ≥10 mIU/mL) in approximately 95% of healthy infants overall (response is lower for infants with lower birth weights) (64) and >90% of healthy adults aged <40 years (111,112).”
BackgroundMcMahon, B. J. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390170087019 · Cited by 201
Wang, C., Ji, D., Chen, J., Shao, Q., Li, B., Liu, J., Wu, V., Wong, A., Wang, Y., Zhang, X., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.06.023 · Cited by 199 · cited 10×
“The number of reported HCV cases in four Appalachian states (Kentucky, Tennessee, Virginia, and West Virginia) increased 364% during 2006– 2012 among persons aged ≤30 years, with injection-drug use as the most common reported risk factor (91).”
BackgroundInfluentialVaccination against Hepatitis B: Comparison of Three Different Vaccination Schedules
Jilg, W., Schmidt, M., & Deinhardt, F. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/160.5.766 · Cited by 185 · cited 2×
“, 11 months) result in higher final antibody levels (142) but might increase the risk for acquisition of HBV infection among persons who have a delayed response to vaccination.”
BackgroundSerologic Diagnosis of Acute and Chronic Viral Hepatitis
Hoofnagle, J., & Di Bisceglie, A. (1991) · Seminars in Liver Disease · doi:10.1055/s-2008-1040426 · Cited by 182 · cited 1×
“The average incubation period is 60 days (range: 40–90 days) from exposure to onset of abnormal serum ALT levels and 90 days (range: 60–150 days) from exposure to onset of jaundice (8,42,43).”
BackgroundOccult hepatitis B virus infection
Allain, J.-P. (2004) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2003.11.007 · Cited by 169
Hepatitis B Virus Infection among Children Born in the United States to Southeast Asian Refugees
Franks, A. L., Berg, C. J., Kane, M. A., Browne, B. B., Sikes, R. K., Elsea, W. R., & Burton, A. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211905 · Cited by 165
Telbivudine Prevents Vertical Transmission From HBeAg-Positive Women With Chronic Hepatitis B
Pan, C. Q., Han, G., Jiang, H., Zhao, W., Cao, M., Wang, C., Yue, X., & Wang, G. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.01.019 · Cited by 152 · cited 1×
“Published evidence indicates that maternal antiviral therapy during pregnancy further reduces perinatal HBV transmission; hence, AASLD suggests antiviral therapy when maternal HBV DNA is >200,000 IU/mL (5,38,39).”
BackgroundPolish, L. B., Shapiro, C. N., Bauer, F., Klotz, P., Ginier, P., Roberto, R. R., Margolis, H. S., & Alter, M. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203123261101 · Cited by 152
Thio, C. L. (2003) · Seminars in Liver Disease · doi:10.1055/s-2003-39951 · Cited by 148
Production and immunological analysis of recombinant hepatitis B vaccine
Emini, E. A., Ellis, R. W., Miller, W. J. W., McAleer, W. J., Scolnick, E. M., & Gerety, R. J. (1986) · Journal of Infection · doi:10.1016/s0163-4453(86)92563-6 · Cited by 147 · cited 1×
“Recombinant HepB vaccines containing yeast-derived HBsAg purified by biochemical and biophysical separation techniques replaced the plasma-derived vaccines in the United States by the late 1980s (64,103,104).”
BackgroundReilly, M., Sawyer, M., Hoerger, T. J., Murphy, T. V., Schillie, S., Hu, D. J., Spradling, P., Byrd, K., Xing, J., Tohme, R. A., et al. (2011) · Cited by 143
Self-citationOutcomes of Infants Born to Women Infected With Hepatitis B
Schillie, S. F., Walker, T. Y., Veselsky, S. L., Crowley, S., Dusek, C., Lazaroff, J., Morris, S. A., Onye, K., Ko, S. C., Fenlon, N., et al. (2015) · PEDIATRICS · doi:10.1542/peds.2014-3213 · Cited by 142 · cited 4×
“1% of infants develop infection (28,29,64); infants born to mothers with high viral loads are at greatest risk for infection despite receipt of HepB vaccine and HBIG (29).”
BackgroundInfluentialSelf-citationOccupational Risk of Hepatitis B Infection in Hospital Workers
Hadler, S. C., Doto, I. L., Maynard, J. E., Smith, J. L., Clark, B. T., Mosley, J. W., Eickhoff, T. C., Himmelsbach, C. K., & Cole, W. R. (1985) · Infection Control · doi:10.1017/s0195941700062457 · Cited by 141 · cited 1×
“Before HepB vaccination was widely implemented, HBV infection was recognized as a common occupational risk among HCP (85,86).”
BackgroundPrevention of Perinatal Hepatitis B Virus Transmission
Nelson, N. P., Jamieson, D. J., & Murphy, T. V. (2014) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piu064 · Cited by 140 · cited 30×
“New strategies for further reducing HBV transmission in this report include testing HBsAg-positive pregnant women for HBV DNA to identify infants at greatest risk for infection and guide the use of maternal antiviral therapy (36,37).”
BackgroundInfluentialSelf-citationThe Increasing Burden of Imported Chronic Hepatitis B — United States, 1974–2008
Mitchell, T., Armstrong, G. L., Hu, D. J., Wasley, A., & Painter, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027717 · Cited by 131 · cited 1×
“Foreign-born persons account for approximately 95% of newly reported chronic infections in the United States (20); the prevalence of chronic HBV infection is approximately 3.”
BackgroundIncreases in Acute Hepatitis B Virus Infections — Kentucky, Tennessee, and West Virginia, 2006–2013
Harris, A. M., Iqbal, K., Schillie, S. F., Britton, J., Kainer, M. A., Tressler, S. R., & Vellozzi, C. J. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6503a2 · Cited by 129 · cited 2×
“During 2009–2013, the combined incidence of acute HBV infection in three states (Kentucky, Tennessee, and West Virginia) increased 114% and was associated with increasing injection-drug use (16).”
BackgroundSelf-citationHurie, M. B., Mast, E. E., & Davis, J. P. (1992) · PEDIATRICS · doi:10.1542/peds.89.2.269 · Cited by 124 · cited 1×
“Prior to universal infant vaccination, the risk for infection was greatest among unvaccinated children living with a person with chronic HBV infection in a household or in an extended family setting (67,77,78).”
BackgroundVaccination Coverage Among Children Aged 19–35 Months — United States, 2016
Hill, H. A., Elam–Evans, L. D., Yankey, D., Singleton, J. A., & Kang, Y. (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6643a3 · Cited by 115
Alter, M. J., Favero, M. S., & Maynard, J. E. (1986) · The Journal of Infectious Diseases · doi:10.1093/infdis/153.6.1149 · Cited by 112 · cited 1×
“Since the initiation of HepB vaccination and additional infection control precautions for hepatitis B in dialysis centers, the incidence of HBV infection among hemodialysis patients has declined approximately 95% (88,89).”
BackgroundCassidy, W. M., Watson, B. M., Ioli, V. A., Williams, K., Bird, S. R., & West, D. J. (2001) · PEDIATRICS · doi:10.1542/peds.107.4.626 · Cited by 109
Lack of Association of Guillain-Barre Syndrome With Vaccinations
Baxter, R. P., Bakshi, N., FIREMAN, B. H., Lewis, E. M., Ray, P., Vellozzi, C. J., & Klein, N. P. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit222 · Cited by 109
Self-citationPrevention of Vertical Transmission of Hepatitis B
Kubo, A., Shlager, L., Marks, A. R., Lakritz, D., Beaumont, C., Gabellini, K., & Corley, D. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2529 · Cited by 106 · cited 30×
“New strategies for further reducing HBV transmission in this report include testing HBsAg-positive pregnant women for HBV DNA to identify infants at greatest risk for infection and guide the use of maternal antiviral therapy (36,37).”
BackgroundInfluentialThe clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics
Kramvis, A. (2016) · Reviews in Medical Virology · doi:10.1002/rmv.1885 · Cited by 106 · cited 1×
“Infection or immunization with one genotype generally confers immunity to all genotypes (7,44,46,47).”
BackgroundSeroprotection after recombinant hepatitis B vaccination among newborn infants: A review
Schillie, S. F., & Murphy, T. V. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.012 · Cited by 105 · cited 7×
“Among healthy adults aged <40 years, 30%–55% and 75% achieve anti-HBs levels ≥10 mIU/mL after the first and second dose, respectively (7,8,64).”
BackgroundInfluentialSelf-citationCandotti, D., Lin, C. K., Belkhiri, D., Sakuldamrongpanich, T., Biswas, S., Lin, S., Teo, D., Ayob, Y., & Allain, J. (2012) · Gut · doi:10.1136/gutjnl-2011-301281 · Cited by 105
(1982) · PubMed · Cited by 102
Simons, B. C., Spradling, P. R., Bruden, D. J. T., Zanis, C., Case, S., Choromanski, T. L., Apodaca, M., Brogdon, H. D., Dwyer, G., Snowball, M., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw142 · Cited by 101
Chronic Hepatitis B Virus Infection
McMahon, B. J. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.08.004 · Cited by 92
Development and production aspects of a recombinant yeast-derived hepatitis B vaccine
Stéphenne, J. (1990) · Vaccine · doi:10.1016/0264-410x(90)90221-7 · Cited by 89
Immune Response of Hepatitis B Vaccine Among Persons With Diabetes
Schillie, S. F., Spradling, P. R., & Murphy, T. V. (2012) · Diabetes Care · doi:10.2337/dc12-0312 · Cited by 88 · cited 4×
“1% for those without diabetes mellitus (112).”
BackgroundInfluentialSelf-citationUpdate: Recommendations to Prevent Hepatitis B Virus Transmission--United States
(1999) · JAMA · doi:10.1001/jama.281.9.790-a · Cited by 84
Silva, A. E., McMahon, B. J., Parkinson, A. J., Sjögren, M. H., Hoofnagle, J. H., & Bisceglie, A. M. D. (1998) · Clinical Infectious Diseases · doi:10.1086/513918 · Cited by 82 · cited 1×
“HBV DNA has been detected in <10% of persons with isolated anti-HBc (70,71), although the presence of detectable HBV DNA might fluctuate (72).”
BackgroundImmunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders
Institute of Medicine (2002) · National Academies Press eBooks · doi:10.17226/10393 · Cited by 81
Increased Risk of Acute Hepatitis B among Adults with Diagnosed Diabetes Mellitus
Reilly, M. L., Schillie, S. F., Smith, E., Poissant, T. M., Vonderwahl, C. W., Gerard, K., Baumgartner, J., Mercedes, L., Sweet, K., Muleta, D. B., et al. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600417 · Cited by 78
Self-citationEffect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians
Hadler, S. C., de Monzon, M. A., Lugo, D. R., & Perez, M. (1989) · Vaccine · doi:10.1016/0264-410x(89)90046-7 · Cited by 77
Jonas, M. M., Lok, A. S.-F., McMahon, B. J., Brown, R. S., Wong, J. B., Ahmed, A. T., Farah, W. H., Mouchli, M. A., Singh, S., Prokop, L. J., et al. (2015) · Hepatology · doi:10.1002/hep.28278 · Cited by 76
Immunization and Bell's Palsy in Children: A Case-Centered Analysis
Rowhani‐Rahbar, A., Klein, N. P., Lewis, N., FIREMAN, B. H., Ray, P., Rasgon, B. M., BLACK, S. B., Klein, J. O., & Baxter, R. P. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws011 · Cited by 75 · cited 1×
“In addition, no evidence of a causal association between rheumatoid arthritis (130), Bell’s palsy (131), autoimmune thyroid disease (132), hemolytic anemia in children (133), anaphylaxis (134), optic neuritis (135), Guillain-Barré Syndrome (136), sudden-onset sensorineural hearing loss (137), or other chronic illnesse…”
BackgroundFeo, T. M. D., Poli, F., Mozzi, F., Moretti, M. P., & Scalamogna, M. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.12.041 · Cited by 73 · cited 1×
“These persons are unlikely to transmit infection except under circumstances in which they are the source of a large exposure, such as a blood transfusion (8,73).”
BackgroundThe underlying mechanisms for the ‘anti-HBc alone’ serological profile
Pondé, R. A. D. A., Cardoso, D. D. P., & Ferro, M. O. (2009) · Archives of Virology · doi:10.1007/s00705-009-0559-6 · Cited by 70 · cited 3×
“IgM anti-HBc often becomes undetectable within 6 months, and IgG anti-HBc predominates and remains detectable for a lengthy period of time, often life-long (65,66).”
BackgroundChun, H., Fieberg, A. M., Hullsiek, K. H., Lifson, A. R., Crum‐Cianflone, N. F., Weintrob, A., Ganesan, A., Barthel, R., Bradley, W. P. L., Agan, B. K., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649885 · Cited by 68
Prevention of Perinatal Transmission of Hepatitis B Virus
Report, M. A. M. W. (1989) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198902000-00008 · Cited by 68
Impaired response to hepatitis B vaccine in HIV infected children
Zuin, G., Principi, N., TORNAGHI, R., Paccagnini, S., Re, M. C., MASSIRONI, E., & Ragni, M. C. (1992) · Vaccine · doi:10.1016/0264-410x(92)90050-t · Cited by 67 · cited 1×
“, hematopoietic stem cell transplant recipients, patients undergoing chemotherapy, and HIV-infected persons) (122,123).”
BackgroundHepatitis B vaccine and central nervous system demyelinating diseases
Halsey, N. A., DUCLOS, P. J., Damme, P. V., & Margolis, H. S. (1999) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199901000-00007 · Cited by 64
A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults
Marsano, L. S., West, D. J., Chan, I. S. F., Hesley, T. M., Cox, J., Hackworth, V., & Greenberg, R. N. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00233-8 · Cited by 64
Schillie, S. F., Xing, J., Murphy, T. V., & Hu, D. J. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2012.01616.x · Cited by 60
Self-citationWiström, J., Ahlm, C., Lundberg, S., Settergren, B., & Tärnvik, A. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00012-2 · Cited by 60
Agerton, T., Mahoney, F. J., Polish, L. B., & Shapiro, C. N. (1995) · Infection Control and Hospital Epidemiology · doi:10.1086/647109 · Cited by 59
Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants
Patel, D. M., Butler, J., Feldman, S., Graves, G. R., & Rhodes, P. G. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70078-7 · Cited by 57 · cited 1×
“1 17 US Department of Health and Human Services/Centers for Disease Control and Prevention <2,000 grams at birth have a decreased response to HepB vaccine administered before age 1 month (118).”
BackgroundHepatitis B Vaccine Administered to Children and Adolescents at Yearly Intervals
Halsey, N. A., Moulton, L. H., O'Donovan, J. C., Walcher, J., THOMS, M. L., Margolis, H. S., & Krause, D. S. (1999) · PEDIATRICS · doi:10.1542/peds.103.6.1243 · Cited by 57
Schillie, S. F., Murphy, T. V., Fenlon, N., Ko, S. C., & Ward, J. W. (2015) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6439a6 · Cited by 57
Self-citationFan, L., Owusu‐Edusei, K., Schillie, S. F., & Murphy, T. V. (2015) · Hepatology · doi:10.1002/hep.28310 · Cited by 55 · cited 1×
“The current strategy of administering HepB vaccine and HBIG within 12 hours of birth for infants born to HBsAg-positive mothers and universal infant vaccination prior to hospital discharge has an incremental cost-effectiveness ratio of $6,957 per quality-adjusted life year (QALY) saved when compared with a strategy of…”
MethodSelf-citationAtypical serological profiles in hepatitis B virus infection
Pondé, R. A. D. A. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1781-9 · Cited by 55 · cited 3×
“IgM anti-HBc often becomes undetectable within 6 months, and IgG anti-HBc predominates and remains detectable for a lengthy period of time, often life-long (65,66).”
BackgroundHomann, C., Krogsgaard, K., Pedersen, C. B., Andersson, P., & Jø, N. (1991) · PubMed · Cited by 54
PREVALENCE OF HEPATITIS B INFECTION AMONG RESIDENTS OF AN INSTITUTION FOR THE MENTALLY RETARDED
Chaudhary, R. K., Perry, E., & CLEARY, T. E. (1977) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112363 · Cited by 50 · cited 1×
“Prior to universal infant vaccination, the risk for infection was greatest among unvaccinated children living with a person with chronic HBV infection in a household or in an extended family setting (67,77,78).”
BackgroundUpdate: Recommendations to Prevent Hepatitis B Virus Transmission—United States
(1995) · JAMA · doi:10.1001/jama.1995.03530080019016 · Cited by 50
Cost-Effectiveness of Hepatitis B Vaccination in Adults With Diagnosed Diabetes
Hoerger, T. J., Schillie, S. F., Wittenborn, J. S., Bradley, C., Zhou, F., Byrd, K. K., & Murphy, T. V. (2012) · Diabetes Care · doi:10.2337/dc12-0759 · Cited by 49 · cited 1×
“Vaccinating adults aged 20–59 years with diabetes mellitus costs $75,094 per QALY saved; cost-effectiveness ratios increase with age at vaccination (149).”
BackgroundSelf-citationRay, P., BLACK, S. B., Shinefield, H. R., Dillon, A., Carpenter, D. M., Lewis, E. M., Ross, P., Chen, R. T., Klein, N. P., & Baxter, R. P. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.112 · Cited by 47 · cited 1×
“In addition, no evidence of a causal association between rheumatoid arthritis (130), Bell’s palsy (131), autoimmune thyroid disease (132), hemolytic anemia in children (133), anaphylaxis (134), optic neuritis (135), Guillain-Barré Syndrome (136), sudden-onset sensorineural hearing loss (137), or other chronic illnesse…”
BackgroundBowman, S., Grau, L. E., Singer, M. C., Scott, G., & Heimer, R. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-820 · Cited by 46
Hepatitis B and C Infection in International Travelers
Johnson, D. F., Leder, K. S., & Torresi, J. (2013) · Journal of Travel Medicine · doi:10.1111/jtm.12026 · Cited by 45 · cited 1×
“Monthly incidence of 25‒420 per 100,000 travelers has been reported among longterm travelers to countries where the disease is endemic (93).”
BackgroundHan, G., Jiang, H., Yue, X., Ding, Y., Wang, C., Wang, G. ‐., & Yang, Y. (2015) · Journal of Viral Hepatitis · doi:10.1111/jvh.12379 · Cited by 45
Fabrizi, F., Dixit, V., Messa, P., & Martin, P. B. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.064 · Cited by 44
Immunopathogenesis of the extrahepatic manifestations of hepatitis B virus infection
Dienstag, J. L. (1981) · Springer Seminars in Immunopathology · doi:10.1007/bf01951493 · Cited by 42 · cited 1×
“, skin rash, arthralgias, and arthritis) also might occur (51).”
BackgroundHepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study
Yu, O., Bohlke, K., Hanson, C. A., Delaney, K. M., Rees, T. G., Zavitkovsky, A., Ray, P., Mullooly, J. P., BLACK, S. B., Benson, P. J., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1354 · Cited by 39 · cited 1×
“In addition, no evidence of a causal association between rheumatoid arthritis (130), Bell’s palsy (131), autoimmune thyroid disease (132), hemolytic anemia in children (133), anaphylaxis (134), optic neuritis (135), Guillain-Barré Syndrome (136), sudden-onset sensorineural hearing loss (137), or other chronic illnesse…”
BackgroundJourdain, G., Ngo‐Giang‐Huong, N., Cressey, T. R., Hua, L., Harrison, L., Tierney, C., Salvadori, N., Decker, L., Traisathit, P., Sirirungsi, W., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1734-5 · Cited by 39
Vaccination Against Hepatitis B in Children and Adolescent Patients on Dialysis
Drachman, R. H., Isacsohn, M., Rudensky, B., & Drukker, A. (1989) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a091892 · Cited by 38
Williams, R., Seña, A. C., Moorman, A. C., Moore, Z., Sharapov, U. M., Drobenuic, J., Hu, D. J., Wood, H., Xing, J., & Spradling, P. R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.078 · Cited by 36
Impaired response to hepatitis B vaccine in children receiving anticancer chemotherapy
Hovi, L., Valle, M., Siimes, M. A., Jalanko, H., & Saarinen, U. M. (1995) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199511000-00002 · Cited by 35 · cited 1×
“, hematopoietic stem cell transplant recipients, patients undergoing chemotherapy, and HIV-infected persons) (122,123).”
BackgroundSudden‐Onset Sensorineural Hearing Loss after Immunization: A Case‐Centered Analysis
Baxter, R. P., Lewis, N., Bohrer, P. S., Harrington, T. A., Aukes, L. L., & Klein, N. P. (2016) · Otolaryngology · doi:10.1177/0194599816639043 · Cited by 34 · cited 1×
“In addition, no evidence of a causal association between rheumatoid arthritis (130), Bell’s palsy (131), autoimmune thyroid disease (132), hemolytic anemia in children (133), anaphylaxis (134), optic neuritis (135), Guillain-Barré Syndrome (136), sudden-onset sensorineural hearing loss (137), or other chronic illnesse…”
Case-centered Analysis of Optic Neuritis After Vaccines: Table 1.
Baxter, R. P., Lewis, E. M., FIREMAN, B. H., Destefano, F. R., Gee, J. M., & Klein, N. P. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw224 · Cited by 32 · cited 1×
“In addition, no evidence of a causal association between rheumatoid arthritis (130), Bell’s palsy (131), autoimmune thyroid disease (132), hemolytic anemia in children (133), anaphylaxis (134), optic neuritis (135), Guillain-Barré Syndrome (136), sudden-onset sensorineural hearing loss (137), or other chronic illnesse…”
BackgroundAgerton, T., Mahoney, F. J., Polish, L. B., et al. (1995) · Infection Control and Hospital Epidemiology · doi:10.2307/30143095 · Cited by 32 · cited 2×
“7%, an increase from 51% in 1992 shortly after implementation of the Needlestick Safety and Prevention Act (35), but well below the Healthy People 2020 target of 90% (32,34).”
BackgroundInfluentialChanging Patterns of Groups at High Risk for Hepatitis B in the United States
(1988) · JAMA · doi:10.1001/jama.1988.03410060029006 · Cited by 31
Tan, K. L. (1994) · JAMA · doi:10.1001/jama.1994.03510350069039 · Cited by 29 · cited 1×
“One study found that of infants born to HBsAg-positive women who were not infected at birth and who did not respond to a primary vaccine series, all developed seroprotective levels of anti-HBs after receipt of 3 additional doses (143).”
BackgroundCost-effectiveness Analysis of the National Perinatal Hepatitis B Prevention Program
Barbosa, C., Smith, E., Hoerger, T. J., Fenlon, N., Schillie, S. F., Bradley, C., & Murphy, T. V. (2014) · PEDIATRICS · doi:10.1542/peds.2013-0718 · Cited by 29 · cited 1×
“htm), which provides case management services to infants born to HBsAg-positive women, also has been demonstrated to decrease infections, increase QALYs saved, and be a costeffective use of resources (148).”
BackgroundSelf-citationFan, L., Owusu‐Edusei, K., Schillie, S. F., & Murphy, T. V. (2014) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000124 · Cited by 29 · cited 2×
“New strategies for further reducing HBV transmission in this report include testing HBsAg-positive pregnant women for HBV DNA to identify infants at greatest risk for infection and guide the use of maternal antiviral therapy (36,37).”
BackgroundSelf-citationHepatitis A and hepatitis B vaccination of patients with chronic liver disease.
Bell, B. P. (2001) · PubMed · Cited by 26
Haber, P., Moro, P. L., Ng, C. S., Lewis, P. W., Hibbs, B. F., Schillie, S. F., Nelson, N. P., Li, R., Stewart, B., & Cano, M. V. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.11.079 · Cited by 25 · cited 2×
“The most frequently reported adverse events for vaccines given in combination were fever (23%), injection site erythema (11%), and vomiting (10%) (138).”
BackgroundSelf-citationHepatitis B Surface Antigen Testing Among Pregnant Women, United States 2014
Kolasa, M., Tsai, Y., Xu, J., Fenlon, N., & Schillie, S. F. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001516 · Cited by 23
Self-citationUpdate: Recommendations to Prevent Hepatitis B Virus Transmission—United States
(1999) · JAMA · doi:10.1001/jama.281.9.790-jwr0303-3-1 · Cited by 21
Are current screening protocols for chronic hepatitis B virus infection adequate?
Mortensen, E., Kamali, A., Schirmer, P., Lucero-Obusan, C. A., Winston, C. A., Oda, G., Winters, M. A., Durfee, J. M., Martinello, R. A., Davey, V. J., et al. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.12.005 · Cited by 18
Newborn hepatitis B vaccination coverage among children born January 2003-June 2005--United States.
(2008) · PubMed · Cited by 16
Risk of immune hemolytic anemia in children following immunization
Naleway, A. L., Belongia, E. A., Donahue, J. G., Kieke, B. A., & Glanz, J. M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.023 · Cited by 14 · cited 1×
“In addition, no evidence of a causal association between rheumatoid arthritis (130), Bell’s palsy (131), autoimmune thyroid disease (132), hemolytic anemia in children (133), anaphylaxis (134), optic neuritis (135), Guillain-Barré Syndrome (136), sudden-onset sensorineural hearing loss (137), or other chronic illnesse…”
BackgroundHepatitis B vaccine and risk of multiple sclerosis
Destefano, F. R., Weintraub, E., & Chen, R. T. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1408 · Cited by 14
Preboth, M. (2001) · PubMed · Cited by 11
Woodruff, B. A., & Vazquez, E. (2002) · American Journal on Mental Retardation · Cited by 10
THE HEALTH DEPARTMENTS, THE M.R.C., AND TRANSFERRED FUNDS
Buller, A. J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92876-2 · Cited by 9
Cost-Effectiveness of Ensuring Hepatitis B Protection for Previously Vaccinated Healthcare Personnel
Hoerger, T. J., Bradley, C., Schillie, S. F., Reilly, M. L., & Murphy, T. V. (2014) · Infection Control and Hospital Epidemiology · doi:10.1086/676865 · Cited by 8 · cited 1×
“Among previously vaccinated current HCP (including those in training), pre-exposure anti-HBs testing followed by revaccination and retesting (if necessary, based on anti-HBs levels), compared with no intervention, was not considered cost-effective with an incremental cost per QALY saved of $3–$4 million at year one an…”
BackgroundSelf-citationChanging Patterns of Groups at High Risk for Hepatitis B in the United States
(1988) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1988.02150100024015 · Cited by 7
Update: Expanded Availability of Thimerosal Preservative-Free Hepatitis B Vaccine
(2000) · JAMA · doi:10.1001/jama.284.8.954-a · Cited by 5
Immunization safety review hepatitis B vaccine and demyelinating neurological disorders
Stratton, K. R., Almario, D. A., & McCormick, M. C. (n.d.) · Cited by 3
Calisti, G., Herman, O., Powley, M., & Haque, T. (2014) · BMJ Case Reports · doi:10.1136/bcr-2013-202191 · Cited by 2 · cited 1×
“Transient HBsAg positivity can occur up to 18 days following vaccination (up to 52 days among hemodialysis patients) and is clinically insignificant (69).”
Background
Research works printed but not linked: 1
- Long SS, Prober CG, Fischer M. Principles and practice of pediatric infectious diseases. 5th ed. Amsterdam, the Netherlands: Elsevier; 2017.
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
“The last vaccine dose should not be given before 24 weeks of age.((89)) Only monovalent HBV vaccine should be used for preterm or term infants younger than 6 weeks.”
BackgroundSexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Hsu, Y.-C., Huang, D. Q., & Nguyen, M. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00760-9 · Cited by 632
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Surveillance of Vaccination Coverage Among Adult Populations —United States, 2018
Lu, P.-J., Hung, M.-C., Srivastav, A., Grohskopf, L. A., Kobayashi, M., Harris, A. M., Dooling, K. L., Markowitz, L. E., Rodriguez-Lainz, A., & Williams, W. W. (2021) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss7003a1 · Cited by 346
“In addition, vaccine can be administered to unvaccinated adults with diabetes aged ≥60 years at the discretion of their HCP (73,74).”
BackgroundSelf-citation
Metadata
- Authors
- Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P.
- Affiliations
- National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention (US)
- University of California, Berkeley (US)
- National Center for Emerging and Zoonotic Infectious Diseases (US)
- Corresponding author
- Schillie, Sarah
- Venue
- MMWR. Recommendations and Reports
- Published
- 2018-01-12
- Volume
- 67
- Issue
- 1
- Pages
- 1-31
- ISSN
- 1057-5987 (ISSN-L)
- 1545-8601
- PMC
- PMC5837403
- OpenAlex
- W2783773804
- Cited by
- 815
- References
- 160
- Citations by year
- 2026: 67 · 2025: 92 · 2024: 76 · 2023: 112 · 2022: 106 · 2021: 123 · 2020: 117 · 2019: 72 · 2018: 47
- FWCI
- 69.79
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- MMWR Recommendations and Reports (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- hepatitis B virus, hepatitis B vaccination, hepatitis B immunoglobulin, HBV DNA testing, post-exposure prophylaxis, occupational exposure, chronic hepatitis B, hepatitis B prevention
- MeSH terms
- Adolescent, Adult, Centers for Disease Control and Prevention, U.S., Child, Child, Preschool, Female, Hepatitis B, Humans, Immunization, Immunization Schedule, Immunization, Secondary, Infant, Infant, Newborn, Male, Pregnancy, United States, Hepatitis B Vaccines, Advisory Committees, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.